August 26, 2011
Local (JPN)

PDF (18KB)

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Announces Reorganization, Reinforcement and Renaming of R&D-related Japan Subsidiary

Tokyo, Japan (August 26, 2011) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will reorganize, reinforce, and rename its domestic subsidiary DAIICHI SANKYO RD ASSOCIE CO., LTD. From of October 1, the subsidiary will be known as DAIICHI SANKYO RD NOVARE CO., LTD.

 

The current DAIICHI SANKYO RD ASSOCIE collaborates with other business units and companies within the Daiichi Sankyo Group to support new drug innovation. Daiichi Sankyo will reinforce DAIICHI SANKYO RD ASSOCIE’s existing capabilities while also centralizing basic pharmaceutical innovation technologies within it. The renamed DAIICHI SANKYO RD NOVARE subsidiary will function as a global research and development platform for the Group, accelerating innovation in first-in-class pharmaceuticals.

 

1. New Company Name

 

New company name

Previous company name

DAIICHI SANKYO RD NOVARE CO., LTD.

DAIICHI SANKYO RD ASSOCIE CO., LTD.

 

2. Date of Change

October 1, 2011

 

 Profile of DAIICHI SANKYO RD NOVARE CO., LTD.

 

 Date of establishment

 October 3, 2006

 President

 Hideyuki Haruyama

 Capitalization

 50 million yen

 Projected number of

 employees

 (as of October 1, 2011)

 Around 300

 Core business overview

 ・Custom production of research materials and intermediates for drug discovery and development

 ・Contract assay development and quantitative and/or qualitative analysis of drug substances

・Technology based drug discovery support and alliance

・Consultation for the evaluation and application of the novel technological platform for drug discovery

・Contract Clinical development
End

Back to index